The global collagen vascular diseases market is anticipated to grow at a considerable CAGR of around 7.5% during the forecast period (2021-2027). The key factor to drive the market growth is the increasing prevalence of collagen vascular diseases such as Scleroderma and arthritis. For instance, according to the Journal of Managed Care and Specialty Pharmacy, the prevalence rates of Scleroderma in the US were 15.1 per 100,000 person-years and 25.9 per 100,000 people respectively. Furthermore, according to the Centers for Disease Control and Prevention, in 2040, an estimated 78.4 million US adults aged 18 years and older will have doctor-diagnosed arthritis among them Two-thirds with arthritis will be women. Also, it is estimated that around 34.6 million adults in the US will report arthritis-attributable activity limitations as well in 2040.
A full report of Collagen Vascular Diseases Market is available at: https://www.omrglobal.com/industry-reports/collagen-vascular-diseases-market
Rising acquisitions, product approval, collaborations among the major players in the market also propel the growth of the market. For instance, in December 2019, Pfizer Inc announced that the US Food and Drug Administration (FDA) has approved XELJANZ XR for once-daily treatment of patients with moderate to severely active rheumatoid arthritis those who have an inadequate response to methotrexate. With this approval, Pfizer Inc will be able to offer patients and their healthcare providers with moderate to severely active ulcerative colitis a convenient one daily dosing treatment option with Xeljianz.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/collagen-vascular-diseases-market
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered-
- By Disease Type
- By Diagnostics
- By Therapeutics
- By End-User
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive AbbVie Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Inc., Pfizer Inc, Beckman Coulter, Inc., and Bayer AG, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Collagen Vascular Diseases Market Report Segment
By Disease Type
- Autoimmune Collagen Vascular Diseases
- Lupus
- Rheumatoid Arthritis
- Scleroderma
- Hereditary Collagen Vascular Diseases
By Diagnostics
- Complete Blood Count
- Erythrocyte Sedimentation Rate (ESR)
- C-Reactive Protein
- Rheumatoid Factor
- Others (Urinalysis with Microscopic Analysis & Serum Creatinine)
By Therapeutics
- Corticosteroids
- Immunosuppressive Agents
- Endothelin Receptor Antagonists
- Others (Calcium Channel Blockers, PDE-5 Inhibitors & Chelating Agents)
By End-Users
- Hospital & Clinics
- Diagnostic Centers
- Research Institutes
This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.
